Literature DB >> 22253470

Off-label use of oncology drugs: the need for more data and then some.

David G Pfister.   

Abstract

Mesh：

Year:  2012        PMID： 22253470     DOI： 10.1200/JCO.2011.38.5567

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  In-gap discounts in Medicare Part D and specialty drug use.

Authors:  Jeah Jung; Wendy Yi Xu; Chelim Cheong
Journal:  Am J Manag Care       Date:  2017-09       Impact factor: 2.229

Review 2.  Cost, coverage, and comparative effectiveness research: the critical issues for oncology.

Authors:  Steven D Pearson
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

Review 3.  Artificial intelligence unifies knowledge and actions in drug repositioning.

Authors:  Zheng Yin; Stephen T C Wong
Journal:  Emerg Top Life Sci       Date:  2021-12-21

Review 4.  Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines.

Authors:  Guangxu Jin; Stephen T C Wong
Journal:  Drug Discov Today       Date:  2013-11-14       Impact factor: 7.851

5.  The Price Elasticity of Specialty Drug Use: Evidence from Cancer Patients in Medicare Part D.

Authors:  Jeah Kyoungrae Jung; Roger Feldman; A Marshall McBean
Journal:  Forum Health Econ Policy       Date:  2017-05-26

Review 6.  Repurposing medicinal compounds for blood cancer treatment.

Authors:  Bronagh McCabe; Fabio Liberante; Ken I Mills
Journal:  Ann Hematol       Date:  2015-06-07       Impact factor: 3.673

7.  Using Drugs as Molecular Probes: A Computational Chemical Biology Approach in Neurodegenerative Diseases.

Authors:  Mohammad Asif Emran Khan Emon; Alpha Tom Kodamullil; Reagon Karki; Erfan Younesi; Martin Hofmann-Apitius
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

8.  The Off-Label Use of Antineoplastics in Oncology Is Limited But Has Notable Scientific Support in a University Hospital Setting.

Authors:  Marta Herrero Fernandez; Raquel Molina Villaverde; Monica Arroyo Yustos; Fatima Navarro Expósito; Jose Luis Lopez Gonzalez; Maria Rosario Luque Infantes; Melchor Alvarez-Mon Soto
Journal:  Front Pharmacol       Date:  2019-10-23       Impact factor: 5.810

9.  Influence of data disclosures on physician decisions about off-label uses: findings from a qualitative study.

Authors:  Melanie C Chansky; Simani M Price; Kathryn J Aikin; Amie C O'Donoghue
Journal:  BMC Prim Care       Date:  2022-04-19

10.  Accelerating precision medicine in metastatic prostate cancer.

Authors:  Joaquin Mateo; Rana McKay; Wassim Abida; Rahul Aggarwal; Joshi Alumkal; Ajjai Alva; Felix Feng; Xin Gao; Julie Graff; Maha Hussain; Fatima Karzai; Bruce Montgomery; William Oh; Vaibhav Patel; Dana Rathkopf; Matthew Rettig; Nikolaus Schultz; Matthew Smith; David Solit; Cora Sternberg; Eliezer Van Allen; David VanderWeele; Jake Vinson; Howard R Soule; Arul Chinnaiyan; Eric Small; Jonathan W Simons; William Dahut; Andrea K Miyahira; Himisha Beltran
Journal:  Nat Cancer       Date:  2020-11-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.